



## New Advances in Juvenile Idiopathic Arthritis (JIA)

Guest Editor:

**Prof. Dr. Isabelle Koné-Paut**

Pediatric rheumatology and  
French reference center of  
autoinflammatory diseases and  
inflammatory amyloidosis,  
Bicêtre hospital, APHP, University  
of Paris Saclay, Gif-sur-Yvette,  
France

Deadline for manuscript  
submissions:

**closed (20 September 2022)**

### Message from the Guest Editor

Juvenile idiopathic arthritis (JIA) is a group of inflammatory joint diseases. Its course, often chronic, affects joint function, sometimes also visual function, and has a lasting impact on quality of life. Despite tremendous therapeutic advances, obtaining short-term remission of the disease and maintaining it over the long term only concerns half of patients. The heterogeneity of JIA is one of the main reasons for treatment failures. Following the example of inflammatory rheumatism in adults, the principle of better targeting for better treatment is entering into current practice. The systemic form of JIA, now considered a multifactorial autoinflammatory disease, was the first to benefit from this strategy with complete remission over a short period of time under interleukin-1 blockade (anakinra) as a main objective. One of the important justifications for this strategy is both to better guarantee a response to treatment and to limit the use of ineffective, expensive and sometimes dangerous therapies. Significant progress is still needed in this field, which requires the integration of multimodal data and their standardization into simple tools that can be used elsewhere.





an Open Access Journal by MDPI

## Editors-in-Chief

**Prof. Dr. Emmanuel Andrès**

Internal Medicine Department,  
University Hospital Strasbourg,  
67000 Strasbourg, France

**Prof. Dr. Kent Doi**

Department of Emergency and  
Critical Care Medicine, University  
of Tokyo, Tokyo 113-8655, Japan

## Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) / CiteScore - Q1 (*General Medicine*)

## Contact Us

*Journal of Clinical Medicine* Editorial  
Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jcm](http://mdpi.com/journal/jcm)  
[jcm@mdpi.com](mailto:jcm@mdpi.com)  
[X@JCM\\_MDPI](https://twitter.com/JCM_MDPI)